The company has substantially boosted its development of the new therapy for ATTR-CM, utilizing the compound. Initial clinical information indicates promising improvements for those affected by the debilitating disease. https://bridgebio029447.blogprodesign.com/63577055/company-advances-cardiac-amyloidosis-therapy-through-the-drug